INTRODUCTION 1
During the last decade, the efforts to combat multidrug-resistant microorganisms mainly 2 focused on gram-positive bacteria, namely methicillin-resistant Staphylococcus aureus 3 (MRSA) and vancomycin-resistant enterococci (VRE) . While a large number of hospitals 4 have implemented more rigorous infection control measures, drug companies have developed 5 novel antimicrobial agents to combat these bacteria, resulting into several new compounds 6 with novel mechanisms of action, e.g. linezolid and daptomycin (65) . Paralleling the 7 development in gram-positive bacteria, infections caused by multidrug-resistant (MDR) gram-8 negative bacilli, have become a growing problem (71). In a recent report the Infectious 9
Disease Society of America specifically addressed three categories of MDR gram-negative 10 bacilli, namely third-generation cephalosporin-resistant Escherichia coli and Klebsiella spp., 11 multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter spp. 12 (69). Unfortunately, and contrary to what happened with gram-positive bacteria, no antibiotic 13 from a new class has been developed specifically for MDR gram-negative bacilli. It might be 14 argued that the glycylcycline tigecycline is an exception from the above stated, but although 15 this drug has in vitro activity against many MDR gram-negative bacilli, the drug was not 16 developed specifically for the purpose of treating such bacteria (63). Moreover, there are now 17
The topics covered in this report are resistance to third-generation cephalosporins in E. coli 27 and K. pneumoniae, multidrug-resistance (resistance to ≥ three antipseudomonal agents) (16) Table 3 . 118 119 Impact of resistance on mortality, LOS and hospital costs 120
Due to the different definitions of the MDR phenotype in P. aeruginosa, the data on clinical 121 and economical impact (Table 4) can not easily be directly compared. Six studies found an 122 impact on mortality and one on LOS, but in all of these studies the isolates were resistant to ≥ 123 4 anti-pseudomonal drugs. One study found no impact of the MDR phenotype on outcome, 124 but isolates in this study were only resistant to ≥ two anti-pseudomonal antibiotics. Two of 125 the studies showing an impact of the MDR phenotype on outcome did not apply matching of 126 controls or multivariate analysis (36), and in one of the studies the detected impact in the 127 univariate analysis disappeared in the multivariate analysis, indicating that other factors than 128 the resistance phenotype were important for the outcome (85). Also, three of the studies 129
showing an impact of the MDR phenotype on outcome compared metallo-β-lactamase (MBL) 130 producing isolates with MBL-negative isolates, and MDR isolates were present also in the 131 control groups. None of the studies were multi-center studies. 132
In addition to the studies presented in Table 4 , a recent case-control study 133
showed an impact of fluoroquinolone-resistant P. aeruginosa on mortality and hospital costs 134 (25). The fluoroquinolone-resistant isolates in the study were also resistant to 1-2 other 135 classes of drugs, i.e. some of them had an MDR phenotype. In the multivariate analysis 136 performed in the same study only imipenem-resistance was associated with increased 137 mortality. The imipenem-resistant isolates in the study were also resistant to a median of 138 three other classes of drugs, implying that all of the isolates in this group were in fact MDR 139
isolates. 140 Six studies were considered relevant for inclusion in this report on the clinical impact of 165 carbapenem-resistant Acinetobacter spp., and two of these studies were conducted on burn 166
141
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at TEL AVIV UNIV on December 25, 2007 aac.asm.org Downloaded from patients ( Table 6 ). The only study performed on patients with BSI found significantly 167 increased mortality in the group of patients infected by carbapenem-resistant Acinetobacter 168 spp (CRA) (38). Also, a study of nosocomial ICU infections found a significantly higher 169 mortality among patients infected with CRA, and the same study showed also a significantly 170 increased LOS (60). One case-control study of nosocomial infections found no significant 171 differences in mortality between carbapenem-resistant and -susceptible isolates, but a more 172 than two-fold increase in hospital LOS (70). Among the two studies of burn patients, one 173 found increased mortality and LOS (82) In Enterobacteriaceae, a recent meta-analysis has found increased mortality in patients with 184 BSI caused by ESBL-producing organisms (66), while a majority of studies of other types of 185 infections have found no significant differences attributable to third generation cephalosporin 186 resistance. The finding is not surprising, partly since Enterobacteriaceae in other specimens 187 may represent colonization rather than infection, and partly because the overall mortality in 188 non-BSI caused by Enterobacteriaceae is generally low. The reason for the increased 189 mortality in BSI caused by ESBL-producing organisms seems to be a delay in effective 190 treatment (2, 46, 75) . With respect to the other parameters considered in this review, the 191 Recently, Paterson and Doi have suggested the term "extreme drug resistance" and the 229 abbreviation "XDR" to complement the two previous terms (55). The same paper suggests 230 that PDR should be used to designate gram-negative bacilli that are resistant to all authorized 231 antimicrobial agents except tigecycline and the polymyxins, and that XDR should be 232 restricted to bacteria that are also resistant to the latter two drugs. Although a standardized 233 terminology is needed, it could be debated whether this use of PDR and XDR is optimal. 234 Semantically, PDR would be an appropriate term for bacteria that are resistant to all 235 authorized agents, a point that has also been made by Falagas et al (21) . Additionally, XDR is 236 already defined internationally as "extensively drug-resistant", and introducing the term 237 "extreme drug resistance" may create confusion (11). An alternative option would therefore 238 be to use the term "extensively drug-resistant" (XDR), for gram-negative bacilli resistant to 239 all authorized agents except tigecycline and the polymyxins, whereas PDR would be 240 restricted to truly pan-drug-resistant bacteria. Attempts to reach an international consensus on 241 
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